Skip to main navigation Skip to search Skip to main content

Nuclear Morphology-Based Assessment of Cell Fates Induced by a Microtubule Targeting Agent as a Single Treatment or Combined with an Oncolytic Virus

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Immunofluorescence microscopy allows for the quantitative assessment of cell fate at single-cell resolution. This is required to analyze heterogeneous cell populations, as the assessment of average values of given parameters does not faithfully describe distinct states of specific subpopulations. As a case in point, we describe a methodology for characterizing the effects of a microtubule targeting agent, 2-methoxestradiol (2ME2), on T24 human bladder cancer cells. We employ an immunofluorescence-based assessment of nuclear morphology, DNA content, and the intracellular distribution pattern of microtubules for the identification/classification of cells undergoing mitosis or mitotic slippage. When combined with imaging-based identification of cells expressing a nonstructural oncolytic virus protein, this approach enables the assessment of the potential for combined treatment with a microtubule targeting agent and an oncolytic virus (e.g., the Epizootic Hemorrhagic Disease Virus-Tel Aviv University, EHDV-TAU).

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press
Pages91-100
Number of pages10
DOIs
StatePublished - 2025

Publication series

NameMethods in Molecular Biology
Volume2926
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Fluorescence microscopy
  • Microtubule targeting agent
  • Mitotic slippage
  • Nuclear morphometry
  • Oncolytic virus

Fingerprint

Dive into the research topics of 'Nuclear Morphology-Based Assessment of Cell Fates Induced by a Microtubule Targeting Agent as a Single Treatment or Combined with an Oncolytic Virus'. Together they form a unique fingerprint.

Cite this